Cannabis Standard Index brings clarity to medical cannabis
The Index allows medical cannabis patients and their doctors to assess and compare products made by different Licensed Producers
TORONTO — Reformulary Group announced the launch of its Cannabis Standard Index. The Index uniformly categorizes medical cannabis products based on objective data, allowing Canadians and the medical community to find accurate, detailed information and to search and compare products.
“We want to help patients, and their doctors make sense of medical cannabis, so we worked with a group of experts to develop a standardized classification system as is the norm with prescription and over-the-counter drugs, but designed explicitly for cannabinoid-based medicine,” said Helen Stevenson, founder and CEO of Reformulary Group in a prepared statement. “The Cannabis Standard Index makes it possible for patients and healthcare professionals to search and compare cannabis products and to determine which are similar or interchangeable.”
The Index allows medical cannabis patients and their doctors to assess and compare products made by different Licensed Producers (LPs) using objective data such as composition, format and form rather than strain name. As there are no industry standards for the naming of strains, some producers may apply strain names to products with different concentrations of cannabinoids. By indexing products using objective data, including the presence of major (THC, CBD) and minor cannabinoids (THCA, CBDA, CBG, CBC, CBN) where the information is available, the Index can help guide reliable prescribing and therapeutic substitutions.